Arrowhead Pharmaceuticals Inc (ARWR) — Cash Flow-to-Debt Ratio
Arrowhead Pharmaceuticals Inc (ARWR) has a Cash Flow-to-Debt Ratio of 0.02x as of September 2025, meaning its operating cash flow of $20.49 Million could theoretically repay 0% of its total liabilities ($881.88 Million) in one year. See Arrowhead Pharmaceuticals Inc (ARWR) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Arrowhead Pharmaceuticals Inc Cash Flow-to-Debt Ratio (1997–2025)
Historical debt coverage capacity for Arrowhead Pharmaceuticals Inc across 29 annual periods. For the full cash flow conversion analysis, see Arrowhead Pharmaceuticals Inc cash conversion from operations.
Annual Cash Flow-to-Debt Ratio for Arrowhead Pharmaceuticals Inc (1997–2025)
Year-by-year debt coverage analysis for Arrowhead Pharmaceuticals Inc. Check Arrowhead Pharmaceuticals Inc (ARWR) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.19x | $179.55 Million | $947.02 Million | ▲ +138.9% |
| 2024 | -0.49x | $-462.85 Million | $948.74 Million | ▼ -51.7% |
| 2023 | -0.32x | $-153.89 Million | $478.39 Million | ▲ +35.3% |
| 2022 | -0.50x | $-136.13 Million | $273.60 Million | ▼ -187.6% |
| 2021 | 0.57x | $171.22 Million | $301.33 Million | ▲ +136.2% |
| 2020 | -1.57x | $-95.39 Million | $60.72 Million | ▼ -196.1% |
| 2019 | 1.64x | $173.03 Million | $105.81 Million | ▲ +156.7% |
| 2018 | -2.88x | $-47.22 Million | $16.37 Million | ▼ -179.0% |
| 2017 | -1.03x | $-23.94 Million | $23.16 Million | ▲ +46.8% |
| 2016 | -1.94x | $-64.43 Million | $33.15 Million | ▲ +33.0% |
| 2015 | -2.90x | $-65.71 Million | $22.65 Million | ▼ -37.9% |
| 2014 | -2.10x | $-35.42 Million | $16.83 Million | ▼ -28.2% |
| 2013 | -1.64x | $-19.03 Million | $11.59 Million | ▲ +17.4% |
| 2012 | -1.99x | $-15.34 Million | $7.72 Million | ▼ -22.6% |
| 2011 | -1.62x | $-5.39 Million | $3.32 Million | ▲ +9.9% |
| 2010 | -1.80x | $-7.70 Million | $4.28 Million | ▲ +66.5% |
| 2009 | -5.37x | $-15.28 Million | $2.84 Million | ▲ +3.6% |
| 2008 | -5.57x | $-27.58 Million | $4.95 Million | ▲ +20.7% |
| 2007 | -7.03x | $-23.87 Million | $3.40 Million | ▼ -38.7% |
| 2006 | -5.07x | $-14.79 Million | $2.92 Million | ▲ +43.0% |
| 2005 | -8.89x | $-9.10 Million | $1.02 Million | ▼ -164.8% |
| 2004 | -3.36x | $-2.31 Million | $689.70K | ▼ -104.8% |
| 2003 | -1.64x | $-157.60K | $96.18K | ▼ -2399.4% |
| 2002 | -0.07x | $-105.83K | $1.61 Million | ▼ -8.2% |
| 2001 | -0.06x | $-81.81K | $1.35 Million | ▲ +9.7% |
| 2000 | -0.07x | $-80.09K | $1.19 Million | ▼ -105.3% |
| 1999 | -0.03x | $-35.22K | $1.08 Million | ▼ -92.0% |
| 1998 | -0.02x | $-46.15K | $2.71 Million | ▼ -1100.9% |
| 1997 | 0.00x | $4.56K | $2.68 Million | — |